Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;32(5):449-60.
doi: 10.1111/dar.12048. Epub 2013 Apr 25.

Pharmacotherapy of amphetamine-type stimulant dependence: an update

Matthew Brensilver  1 , Keith G Heinzerling, Steven Shoptaw
Affiliations
Review

Pharmacotherapy of amphetamine-type stimulant dependence: an update

Matthew Brensilver et al. Drug Alcohol Rev. 2013 Sep.

Abstract

Issues: Methamphetamine- or amphetamine-type stimulants are the second most frequently used illicit drug worldwide, second only to cannabis. Behavioural treatments are efficacious, but their impact is limited underscoring the need for other treatment options, notably, pharmacotherapy.

Approach: A review of randomised controlled trials of pharmacotherapies for methamphetamine- or amphetamine-type stimulants was performed using PubMed and Google Scholar databases. Evidence for efficacy of medications is reported.

Key findings: Clinical trials have yielded no broadly effective pharmacotherapy. Promising signals have been observed for methylphenidate, naltrexone, bupropion and mirtazapine in subgroups of patients in reducing stimulant use (e.g. patients with less severe dependence at baseline and men who have sex with men), though none has produced an unambiguous, replicable signal of efficacy.

Implications: Problems in Phase II trials, including high dropout rates, missing data and a lack of agreement on outcomes, complicate efforts to find a broadly effective pharmacotherapy for amphetamine-type stimulant disorders. Efforts to address these problems include calls for better validation of pharmacological target exposure, receptor binding and functional modulation. As well, there is a need for agreement in using findings from preclinical and early phases of the medication development process for selecting better pharmacotherapy candidates.

Conclusion: After over 20 years of efforts worldwide to develop a broadly effective medication for dependence on methamphetamine- or amphetamine-type stimulants, no candidate has emerged. This highlights the need for new compounds, consistent and stringent research methods, better integration between preclinical and clinical stages of medication development, and improved collaboration between government, industry and researchers.

Keywords: agonist; amphetamine; methamphetamine; pharmacogenetics; pharmacotherapy.

PubMed Disclaimer

References

    1. United Nations Office on Drugs and Crime. World Drug Report, 2012. Vienna, Austria: 2012.
    1. Degenhardt LHW. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55–70. - PubMed
    1. Welfare AIoHa. 2010 National Drug Strategy Household Survey Report. 2011. Australian Institute of Health and Welfare; 2011.
    1. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102 (Suppl 1):130–5. Epub 2007/05/12. - PubMed
    1. Brecht ML, O’Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29:89–106. - PubMed

Publication types

MeSH terms